Key Drivers
- High Profitability
- Low Leverage
- Cash Flow
AIAI Summary
REGN is now a concentrated execution trade: its strong balance sheet and valuation support upside only if DUPIXENT sustains growth and EYLEA HD offsets biosimilar erosion while upcoming pipeline catalysts rebuild credibility after the Fianlimab failure; investors should wait for evidence of improved cash conversion and clinical delivery before assuming the selloff is a buying opportunity.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Profitability
- •Low Leverage
- •Cash Flow
REGN offers strong profitability, a robust balance sheet, and reasonable valuation, but investors should monitor weakening liquidity, cash conversion, and modest margin pressure.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support tested
- •Weak momentum
REGN remains bearish after a ~5% decline over the last month, with support at $774–$775 offering bounce potential but a break lower signaling risk unless it reclaims $793–$810.
Approximately 5% decline from the $852 high indicates sustained selling pressure
Sentiment & News
Key News Insights:
- •Lead Plaintiff Deadline
- •Securities Class Action
- •Product Growth Pipeline
Regeneron faces escalating securities litigation ahead of the lead-plaintiff deadline, offset by management's growth outlook for EYLEA HD, DUPIXENT, and pipeline catalysts.
Litigation may pressure investor sentiment near term, while product momentum supports longer-term fundamentals
Similar Companies in Healthcare
Other companies in the same sector with AI ratings